Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $104M | $102M | $113M | $117M | $138M | $131M | $97.9M | $106M | $91.0M | $85.3M |
| Revenue growth | — | -2.4% | 10.8% | 3.8% | 17.8% | -5.5% | -25.0% | 8.6% | -14.4% | -6.2% |
| Gross profit | $58.4M | $52.0M | $61.6M | $64.3M | — | — | $37.1M | $50.5M | $44.9M | $42.5M |
| Gross margin | 55.9% | 51.0% | 54.6% | 54.8% | — | — | 37.8% | 47.4% | 49.3% | 49.9% |
| Operating income | -$73.2M | -$58.4M | -$48.2M | -$51.8M | -$51.0M | -$67.5M | -$116M | -$76.6M | -$127M | -$110M |
| Operating margin | -70.1% | -57.3% | -42.6% | -44.2% | -36.9% | -51.7% | -118.6% | -72.0% | -140.1% | -129.2% |
| Net income | -$76.0M | -$60.5M | -$59.0M | -$64.8M | -$53.0M | -$59.2M | -$190M | -$74.7M | -$139M | -$74.9M |
| Net margin | -72.8% | -59.4% | -52.2% | -55.3% | -38.4% | -45.4% | -194.1% | -70.2% | -152.6% | -87.8% |
| EPS (diluted) | -$2.62 | -$1.84 | -$1.49 | -$0.97 | -$0.74 | -$0.78 | -$2.43 | -$0.94 | -$0.52 | -$0.20 |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$39.1M | -$24.1M | -$25.2M | -$35.2M | -$15.4M | -$44.1M | -$89.4M | -$43.3M | -$143M | -$74.3M |
| Capital expenditures | $5.07M | $1.57M | $372K | $2.53M | $12.7M | $13.3M | $3.83M | $2.83M | $8.36M | $8.30M |
| Free cash flow | -$44.2M | -$25.7M | -$25.6M | -$37.7M | -$28.1M | -$57.3M | -$93.2M | -$46.1M | -$152M | -$82.6M |
| Share buybacks | — | — | — | — | — | $0.00 | $563K | $5.41M | $40.5M | $0.00 |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $35.0M | $58.1M | $95.4M | $21.7M | $68.5M | $28.5M | $81.3M | $51.7M | $167M | $121M |
| Total assets | $306M | $287M | $304M | $265M | $325M | $275M | $390M | $323M | $612M | $568M |
| Total liabilities | $253M | $256M | $232M | $111M | $186M | $181M | $161M | $160M | $141M | $143M |
| Long-term debt | — | — | — | — | — | — | $64.9M | $63.5M | $299K | — |
| Shareholders' equity | $53.2M | $30.9M | $72.1M | $154M | $139M | $94.6M | -$81.5M | -$148M | $472M | $424M |
| Retained earnings | -$439M | -$500M | -$559M | -$624M | -$677M | -$736M | -$926M | -$1.00B | -$1.19B | -$1.26B |
| Shares (wtd avg diluted) | 29.2M | 38.8M | 49.3M | 66.8M | 72.0M | 75.8M | 78.3M | 79.2M | 353M | 382M |
Every figure is extracted from STANDARD BIOTOOLS INC.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.